The FDA has approved a new noninvasive stereotactic radiotherapy system to treat cancer in breast tissue.
Indications: The GammaPod system is intended for use in the noninvasive stereotactic delivery of a radiation dose to a portion of the breast in conjunction with breast conserving treatment.
Administration: The system uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a 2-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation.
Efficacy and safety: Approval is based on a study of 17 individuals that showed the prescribed dose was delivered to the breast tumor with minimal radiation-induced side effects such as skin redness or erythema.
FDA clears stereotactic radiotherapy system for use in treating breast cancer [news release]. Silver Spring, MD: FDA. December 22, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590313.htm... Accessed December 31, 2017.
This Week's Must Reads
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489
Obesity tied to higher risk of clear cell RCC, Callahan CL et al. Cancer Epidemiol. 2018 Jul 18. doi: 10.1016/j.canep.2018.07.002
Partial nephrectomy for localized RCC, Cahn D et al. AUA Annual Meeting, Abstract PD07-04
Must Reads in Breast Cancer
Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.
Study could clarify CTC-based staging of metastatic breast cancer , Davis A et al. ASCO 2018 Poster 1019.
Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer, Baselga et al. ASCO Abstract LBA1006.
Brain met outcomes similar for NSCLC, breast cancer patients, Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Ketorolac during primary breast cancer surgery bettered diclofenac, Desmedt C et al. J Natl Cancer Inst. 2018 Apr 30. doi: 10.1093/jnci/djy042.